LX
Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
$1.76 +0.57% (+$0.01)
1M -21.52%
Market Cap $781.8M
P/E Ratio -
Div. Yield -
ROE 40.40%
Bulios Fair Price
$1.99
13.1% upside
Current Price
$1.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LXRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
22 /100
Expensive P/S 18.85x
P/B 4.48x
P/E N/A
Growth
80 /100
Growing Rev. growth 610.25%
Book val. growth 2.81%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 98.85%
FCF margin 192.24%
Net margin 147.38%
Quality
2 /100
Poor ROIC 23.00%
Asset turnover 0.17x
ROE 40.40%
Debt
68 /100
Low Debt/Equity 0.34x
Int. coverage -6.29x
Current ratio 13.37x
Stability
32 /100
Unstable Beta 1.03x
Profitable years 0
Rev. volatility 1,245.19%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael S. Exton
Employees
81
Headquarters
The Woodlands
Upcoming events
05 NOV
Earnings
Upcoming earnings report